Trade-Ideas LLC identified

Cambrex

(

CBM

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Cambrex as such a stock due to the following factors:

  • CBM has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $21.1 million.
  • CBM has traded 7,035 shares today.
  • CBM is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CBM with the Ticky from Trade-Ideas. See the FREE profile for CBM NOW at Trade-Ideas

More details on CBM:

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. CBM has a PE ratio of 27. Currently there is 1 analyst that rates Cambrex a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Recommends

The average volume for Cambrex has been 362,300 shares per day over the past 30 days. Cambrex has a market cap of $1.7 billion and is part of the health care sector and drugs industry. The stock has a beta of 2.33 and a short float of 5.2% with 5.49 days to cover. Shares are up 21% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Cambrex as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 12.0%. Since the same quarter one year prior, revenues rose by 22.2%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • CBM has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.36, which illustrates the ability to avoid short-term cash problems.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • 46.95% is the gross profit margin for CAMBREX CORP which we consider to be strong. It has increased from the same quarter the previous year. Along with this, the net profit margin of 15.39% is above that of the industry average.
  • Net operating cash flow has significantly increased by 153.79% to $89.77 million when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 115.01%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.